Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — H1 2012 Earnings Presentation
17 slides from Novo Nordisk A/s Class B's earnings presentation, Aug 9, 2012
Slide 1: Investor conference call First six months of 2012
Investor conference call Investor conference call First six months of 2012
Slide 2: Agenda
Investor conference call First six months of 2012 Slide no 2 Agenda Introduction by Lars Rebien Sørensen, CEO Sales update by Lars Rebien Sørensen, CEO R&D update by Mads Krogsgaard Thomsen, CSO Financials and outlook by Jesper Brandgaard, CFO Questions & answers session
Slide 3: Forward-looking statements
Investor conference call First six months of 2012 Slide no 3 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2011 and Form 20-F, both filed with the SEC in Feb
Slide 4: Highlights – first six months of 2012
Investor conference call First six months of 2012 Slide no 4 Highlights – first six months of 2012 Sales development • Sales increased by 12% in local currencies and 17% in Danish kroner: • North America and International Operations increased by 19% and 17% in local currencies, respectively • Victoz
Slide 5: North America continues to drive sales growth
Investor conference call First six months of 2012 Slide no 5 North America continues to drive sales growth – first six months of 2012 Sales as reported Growth analysis Region China Local currencies Growth Share of +25% growth Japan & Korea North America 19% 64% +10% 8% Europe 2% 6% 9% North America
Slide 6: Modern insulins and Victoza continue to drive growth
Investor conference call First six months of 2012 Slide no 6 Modern insulins and Victoza® continue to drive growth – first six months of 2012 Sales as reported Growth analysis Other Local currencies Growth Share of Norditropin® (3%) growth +15% 3% Modern insulins 15% 54% NovoSeven® 7% Human insulins
Slide 7: Rebound in insulin sales growth rate is sustained
Investor conference call First six months of 2012 Slide no 7 Rebound in insulin sales growth rate is sustained Novo Nordisk global quarterly insulin sales Key observations MAT growth rate Growth Elements driving rebound in insulin growth rate Quarter vs. same quarter previous year rate… • Annualisat
Slide 8: Victoza continues to exhibit solid growth
Investor conference call First six months of 2012 Slide no 8 Victoza® continues to exhibit solid growth Reported Victoza® sales Victoza® H1 2012 sales split per region DKK North America Europe China billion Int. Operations Japan & Korea 5%1% 6% 26% 62% Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Sales of DKK 4
Slide 9: Tresiba and Ryzodeg regulatory update
Investor conference call First six months of 2012 Slide no 9 Tresiba® and Ryzodeg® regulatory update • New drug applications (NDAs) submitted to FDA on 29 September 2011 USA • FDA reviews ongoing, advisory committee meeting tentatively scheduled 8 November 2012 • NDAs submitted to EMA on 26 Septembe
Slide 10: DUAL I, the first phase 3a trial for IDegLira, completed
Investor conference call First six months of 2012 Slide no 10 DUALTM I, the first phase 3a trial for IDegLira, a fixed ratio combination of Victoza® and Tresiba®, completed DUALTM I (NN9068-3690) trial design1 Headline results Tresiba® Victoza® IDegLira IDegLira once-daily (n=834) Baseline HbA1c 8.3
Slide 11: Semaglutide selected as once-weekly GLP-1 candidate to enter phase 3
Investor conference call First six months of 2012 Slide no 11 Semaglutide selected as Novo Nordisk’s once-weekly GLP-1 candidate to enter phase 3 Comparison of HbA1c reductions over 12 weeks Summary and conclusions Semaglutide Liraglutide • 12-week, randomised, double-blind, placebo-controlled Basel
Slide 12: Other key events within Research and Development
Investor conference call First six months of 2012 Slide no 12 Other key events within Research and Development Diabetes care • A phase 1 trial has been initiated for OI362GT, a new oral insulin analogue • In May, Levemir® was approved for use in children aged 2-5 years in the US • NovoMet®, the fixe
Slide 13: Financial results – first six months of 2012
Investor conference call First six months of 2012 Slide no 13 Financial results – first six months of 2012 DKK million H1 2012 H1 2011 Change Sales 37,219 31,694 17% Gross profit 30,392 25,478 19% Gross margin 81.7% 80.4% Sales and distribution costs 10,053 8,893 13% Percentage of sales 27.0% 28.1%
Slide 14: US dollar and Japanese Yen remains significantly above 2011 average
Investor conference call First six months of 2012 Slide no 14 US dollar and Japanese Yen remains significantly above 2011 average 650 Spot rates Quarterly average Annual average Currency 2011 2012 Current assumptions1 average average rate2 600 USD/DKK USD 536 579 601 550 JPY 6.73 7.28 7.67 CNY 83 91
Slide 15: Financial outlook 2012
Investor conference call First six months of 2012 Slide no 15 Financial outlook 2012 Expectations Previous expectations 9 August 2012 27 April 2012 Sales growth - local currencies 9-12% 8-11% Sales growth - reported Around 7 percentage points higher Around 4 percentage points higher Operating profit
Slide 16: Closing remarks
Investor conference call First six months of 2012 Slide no 16 Closing remarks Solid market performance Promising pipeline • +10% annual diabetes care market growth • The only company with two new generation driven by diabetes prevalence1 insulins submitted for approval • 25% market share in diabetes
Slide 17: Investor information
Investor conference call First six months of 2012 Slide no 17 Investor information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on Investor Relations the New York S